Clinical trials
Brain Metastases From Solid Tumors clinical trials
Below are recruiting brain metastases from solid tumors clinical trials, each written for real people, not researchers. We’re tracking 533 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07448116RecruitingPhase 1/Phase 2
Testing MCLA-129 plus ensartinib for advanced solid tumors
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07446153RecruitingPhase 1/Phase 2
HRS-8364 for advanced solid tumors
This trial tests a new medicine, HRS-8364, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if the drug can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–75 - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Orange, CaliforniaAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT07415863RecruitingPhase 1/Phase 2
Study of SYS6043 for advanced solid tumors
This trial tests a new drug, SYS6043, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
Beijing, Beijing MunicipalityAges 18–75 - NCT07408258RecruitingPhase 1
Safety and dosing study of ONC-783 for advanced solid tumors
This trial tests an experimental drug called ONC-783 for people with advanced pancreatic, ovarian, colorectal, or breast cancer. The goal is to see if the drug is safe, how it works in the body, and whether it can help shrink tumors.
New York, New YorkAges 18 years+ - NCT07356453RecruitingPhase 1
Study of PARG inhibitor FORX-428 for advanced solid tumors
This trial tests a new drug called FORX-428, which targets a protein called PARG, in people with advanced solid tumors. It is for patients whose cancer has not responded to prior treatments and who have specific genetic changes, such as BRCA mutations.
Palo Alto, CaliforniaAges 18 years+ - NCT07360314RecruitingPhase 1
A new drug targeting Ly6E for advanced solid tumors
This trial tests a new drug called M7437 that targets a protein (Ly6E) found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT07349160RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
BeijingAges 19–70 - NCT07339176RecruitingPhase 1/Phase 2
A trial of N17350 injected into tumors for advanced solid cancers
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07304128RecruitingPhase 1
PLB-002 for advanced solid tumors study
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07275073RecruitingPhase 1
JMT106 for advanced solid tumors
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
ZhejiangAges 18 years+ - NCT07274813RecruitingEarly Phase 1
Study of HLX37 for advanced solid tumors that haven't responded to treatment
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
ShanghaiAges 18–75 - NCT07260591RecruitingPhase 1
VSV-02 for advanced solid tumors that need new options
This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.
Xinxiang, HenanAges 18 years+ - NCT07264803RecruitingPhase 2
Tumor testing to guide treatment for advanced cancers
This trial uses a patient's own tumor tissue to test which drugs might work best for cancers that have returned or not responded to previous treatments. It focuses on advanced gastric cancer and other solid tumors.
Jinan, ShandongAges 18–75 - NCT07256782RecruitingPhase 1/Phase 2
A study of QLC5508 combinations for advanced solid tumors
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
ShanghaiAges 18 years+ - NCT07229898RecruitingPhase 1
GEN-725 tablets for advanced solid tumors
This trial tests a new tablet called GEN-725 for people with advanced solid tumors that have stopped responding to standard treatments or cannot tolerate them. It aims to see if the drug is safe and how it affects the body, and may be an option if you've had prior treatment with PD-1/PD-L1 inhibitors that stopped working at least 6 months ago.
HarbinAges 18–75 - NCT05528341RecruitingPhase 1
CAR NK cell treatment trial for solid tumor cancers
This Phase 1 study tests a lab-made immune cell treatment (CAR-NK92 cells) for people with solid tumors that have not responded to earlier treatments. The goal is to see how safe it is and whether it can shrink tumors or help control cancer.
Xinxiang, HenanAges 18–75 - NCT07208773RecruitingPhase 1/Phase 2
Study of YL201 and Ivonescimab for advanced solid tumors
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT05473624RecruitingPhase 1
Test drug HRS-1167 for advanced cancers that need new options
This early study (Phase 1) tests whether HRS-1167 can be given safely to people with advanced solid tumors. It also looks for early signs of activity, especially in cancers with HRR gene mutations (like ovarian, breast, pancreatic, and prostate cancers).
Beijing, Beijing MunicipalityAges 18 years+ - NCT06669975RecruitingPhase 1/Phase 2
Testing AP402 for her2-positive advanced solid tumors
This trial tests an experimental drug called AP402 for people with HER2-positive solid tumors that have spread or cannot be removed by surgery, and who have no standard treatment options left. The goal is to see if AP402 can shrink tumors or slow their growth.
Macquarie, New South WalesAges 18 years+ - NCT05263960RecruitingPhase 1/Phase 2
CM350 drug study for advanced solid tumors
This trial tests CM350 in people with advanced solid cancers that are hard to treat with standard options. It may help by finding a safe dose and whether the drug can work against these cancers.
Chengdu, SichuanAges 18–75 - NCT07141706RecruitingPhase 1
Testing DB-1317 in advanced solid tumors
This trial tests an investigational drug (DB-1317) that targets a protein called ADAM9, found on some solid tumors. It is for people with advanced cancers that have not responded to other treatments, and aims to see if the drug is safe and works.
Los Angeles, CaliforniaAges 18 years+ - NCT07135128RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
Jinan, ShandongAges 18 years+
Hear when a new Brain Metastases From Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain metastases from solid tumors?
- Yes. Clin2 currently lists 533 recruiting brain metastases from solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain metastases from solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain metastases from solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.